Department of Medicine, University of Colorado Denver School of Medicine, Denver, Colorado, USA.
BMC Health Serv Res. 2012 Jan 24;12:20. doi: 10.1186/1472-6963-12-20.
Global coronary heart disease (CHD) risk assessment is recommended to guide primary preventive pharmacotherapy. However, little is known about physicians' understanding and use of global CHD risk assessment. Our objective was to examine US physicians' awareness, use, and attitudes regarding global CHD risk assessment in clinical practice, and how these vary by provider specialty.
Using a web-based survey of US family physicians, general internists, and cardiologists, we examined awareness of tools available to calculate CHD risk, method and use of CHD risk assessment, attitudes towards CHD risk assessment, and frequency of using CHD risk assessment to guide recommendations of aspirin, lipid-lowering and blood pressure (BP) lowering therapies for primary prevention. Characteristics of physicians indicating they use CHD risk assessments were compared in unadjusted and adjusted analyses.
A total of 952 physicians completed the questionnaire, with 92% reporting awareness of tools available to calculate CHD global risk. Among those aware of such tools, over 80% agreed that CHD risk calculation is useful, improves patient care, and leads to better decisions about recommending preventive therapies. However, only 41% use CHD risk assessment in practice. The most commonly reported barrier to CHD risk assessment is that it is too time consuming. Among respondents who calculate global CHD risk, 69% indicated they use it to guide lipid lowering therapy recommendations; 54% use it to guide aspirin therapy recommendations; and 48% use it to guide BP lowering therapy. Only 40% of respondents who use global CHD risk routinely tell patients their risk. Use of a personal digital assistant or smart phone was associated with reported use of CHD risk assessment (adjusted OR 1.58; 95% CI 1.17-2.12).
Reported awareness of tools to calculate global CHD risk appears high, but the majority of physicians in this sample do not use CHD risk assessments in practice. A minority of physicians in this sample use global CHD risk to guide prescription decisions or to motivate patients. Educational interventions and system improvements to improve physicians' effective use of global CHD risk assessment should be developed and tested.
全球冠心病(CHD)风险评估被推荐用于指导初级预防药物治疗。然而,对于医生在临床实践中对全球 CHD 风险评估的理解和使用情况知之甚少。我们的目的是调查美国医生对临床实践中全球 CHD 风险评估的认识、使用和态度,以及这些认识、使用和态度如何因医生专业而有所不同。
我们采用了一项基于网络的对美国家庭医生、普通内科医生和心脏病专家的调查,调查了他们对计算 CHD 风险的工具的认识、CHD 风险评估的方法和使用、对 CHD 风险评估的态度,以及使用 CHD 风险评估来指导阿司匹林、降脂和降压(BP)治疗推荐用于一级预防的频率。在未调整和调整分析中比较了表明使用 CHD 风险评估的医生的特征。
共有 952 名医生完成了问卷,其中 92%的医生报告说知道可以计算 CHD 全球风险的工具。在那些知道这些工具的人中,超过 80%的人认为 CHD 风险计算是有用的,可以改善患者的护理,并有助于更好地决定是否推荐预防性治疗。然而,只有 41%的医生在实践中使用 CHD 风险评估。报告的 CHD 风险评估的最常见障碍是太耗时。在计算全球 CHD 风险的受访者中,69%的人表示他们使用该评估来指导降脂治疗建议;54%的人表示他们使用该评估来指导阿司匹林治疗建议;48%的人表示他们使用该评估来指导 BP 降低治疗建议。只有 40%的经常使用全球 CHD 风险的受访者会告诉患者他们的风险。使用个人数字助理或智能手机与报告的 CHD 风险评估使用相关(调整后的 OR 1.58;95%CI 1.17-2.12)。
报告的计算全球 CHD 风险的工具的认识似乎很高,但本研究样本中的大多数医生并未在实践中使用 CHD 风险评估。本研究样本中的少数医生使用全球 CHD 风险来指导处方决策或激励患者。应制定和测试改善医生有效使用全球 CHD 风险评估的教育干预措施和系统改进措施。